Document:

NEITHER THIS SECURITY NOR
THE SECURITIES AS TO WHICH THIS SECURITY MAY BE EXERCISED HAVE BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES
COMMISSION OF ANY STATE IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES
ACT”), AND, ACCORDINGLY, MAY NOT BE OFFERED OR SOLD EXCEPT PURSUANT TO AN EFFECTIVE REGISTRATION STATEMENT UNDER THE SECURITIES
ACT OR PURSUANT TO AN AVAILABLE EXEMPTION FROM, OR IN A TRANSACTION NOT SUBJECT TO, THE REGISTRATION REQUIREMENTS OF THE SECURITIES ACT
AND IN ACCORDANCE WITH APPLICABLE STATE SECURITIES LAWS AS EVIDENCED BY A LEGAL OPINION OF COUNSEL TO THE TRANSFEROR TO SUCH EFFECT, THE
SUBSTANCE OF WHICH SHALL BE REASONABLY ACCEPTABLE TO THE COMPANY. THIS SECURITY AND THE SECURITIES ISSUABLE UPON EXERCISE OF THIS SECURITY
MAY BE PLEDGED IN CONNECTION WITH A BONA FIDE MARGIN ACCOUNT OR OTHER LOAN SECURED BY SUCH SECURITIES.

 

COMMON STOCK PURCHASE WARRANT

Wikisoft Corp.

 

Warrant Shares: 500,000

Date of Issuance: June 8,
2021 (the “Issuance Date”)

 

THIS
COMMON STOCK PURCHASE WARRANT (the “Warrant”) certifies that, for value committed to (in connection with the common stock
purchase agreement June 7, 2021, in the amount of $750,000 by the Company (as defined below) to the Investor (as defined below)) (the
“Agreement”), TRITON FUNDS LP (the “Investor” and including any permitted and registered assigns, the “Holder”),
is entitled, upon the terms and subject to the limitations on exercise and the conditions hereinafter set forth, at any time during the
Exercise Period, to purchase from Wikisoft Corp., a Nevada corporation (the “Company”), 500,000 shares of the Company’s
common stock (as defined below) (the “Warrant Shares”) at the Exercise Price per share then in effect. The number of Warrant
Shares for which this Warrant may be exercised is subject to adjustment in accordance with the terms hereof.

 

Capitalized
terms used in this Warrant shall have the meanings set forth in the Agreement unless otherwise defined in the body of this Warrant or
in Section 14 below. For purposes of this Warrant, the term “Exercise Price” shall mean a $190,000,000 Valuation
(the “Valuation Cap”), subject to adjustment as provided herein (including but not limited to cashless exercise), and the
term “Exercise Period” shall mean the period commencing on Issuance Date and ending on 5:00 p.m. eastern time on the three-year
anniversary of such date.  

 

1. EXERCISE
OF WARRANT.

 

(a) Mechanics
of Exercise.  Subject to the terms and conditions hereof, the rights represented by this Warrant may be exercised in whole or in
part at any time or times during the Exercise Period by delivery of a written notice, in the form attached hereto as Exhibit A (the
“Exercise Notice”), of the Holder’s election to exercise this Warrant.  The Holder shall not be required to deliver
the original Warrant in order to effect an exercise hereunder.  Partial exercises of this Warrant resulting in purchases of a portion
of the total number of Warrant Shares available hereunder shall have the effect of lowering the outstanding number of Warrant Shares purchasable
hereunder in an amount equal to the applicable number of Warrant Shares purchased. On or before the second Trading Day (the “Warrant
Share Delivery Date”) following the date on which the Company shall have received the Exercise Notice, which Exercise Notice must
be received by the Company prior to 11 a.m., New York, New York time to count as received on such date, and upon receipt by the Company
of payment to

 

    	 	1	 

    	 

    

 

the Company of an amount equal to the applicable Exercise Price multiplied by the number of Warrant Shares as to which all
or a portion of this Warrant is being exercised (the “Aggregate Exercise Price” and together with the Exercise Notice, the
“Exercise Delivery Documents”) in cash or by wire transfer of immediately available funds (or by cashless exercise if permitted
under the terms of this Warrant, in which case there shall be no Aggregate Exercise Price provided), the Company shall (or direct its
transfer agent to) issue and dispatch by overnight courier to the address as specified in the Exercise Notice, a certificate, registered
in the Company’s share register in the name of the Holder or its designee, for the number of shares of Common Stock to which the
Holder is entitled pursuant to such exercise. Upon delivery of the Exercise Delivery Documents, the Holder shall be deemed for all corporate
purposes to have become the holder of record of the Warrant Shares with respect to which this Warrant has been exercised, irrespective
of the date of delivery of the certificates evidencing such Warrant Shares. If this Warrant is submitted in connection with any exercise
and the number of Warrant Shares represented by this Warrant submitted for exercise is greater than the number of Warrant Shares being
acquired upon an exercise, then the Company shall as soon as practicable and in no event later than three Business Days after any exercise
and at its own expense, issue a new Warrant (in accordance with Section 6) representing the right to purchase the number of Warrant
Shares purchasable immediately prior to such exercise under this Warrant, less the number of Warrant Shares with respect to which this
Warrant is exercised.

 

If
the Company fails to cause its transfer agent to transmit to the Holder the respective shares of Common Stock by the respective Warrant
Share Delivery Date, then the Holder will have the right to rescind such exercise in Holder’s sole discretion.

If
the Company fails to have its Registration Statement filed for the shares to be issued and registered pursuant to the Agreement declared
effective by the Securities and Exchange Commission, or if any time after 180 days of the Issuance Date of this Warrant, there is no
effective registration statement of the Company covering the Holder’s immediate resale of the Warrant Shares without any limitations,
then the Holder may elect to receive Warrant Shares pursuant to a cashless exercise, in lieu of a cash exercise, equal to the value of
this Warrant determined in the manner described below (or of any portion thereof remaining unexercised) by surrender of this Warrant
and a Notice of Exercise, in which event the Company shall issue to Holder a number of Common Stock computed using the following formula:

 

X = Y (A-B)

A

 

	Where  	X =	the number of Shares to be issued to Holder.
	 	 	 
	 	Y =	
    the number of Warrant Shares that the Holder elects to

    purchase under this Warrant (at the date of such calculation).

	 	 	 
	 	A =	the Market Price (at the date of such calculation).
	 	 	 
	 	B =	Exercise Price (as adjusted to the date of such calculation).

 

(b) No
Fractional Shares.  No fractional shares shall be issued upon the exercise of this Warrant as a consequence of any adjustment pursuant
hereto. All Warrant Shares (including fractions) issuable upon exercise of this Warrant may be aggregated for purposes of determining
whether the exercise would result in the issuance of any fractional share. If, after aggregation, the exercise would result in the issuance
of a fractional share, the Company shall, in lieu of issuance of any fractional share, pay to the Holder otherwise entitled to such fraction
a sum in cash equal to the product resulting from multiplying the then-current fair market value of a Warrant Share by such fraction.

    	 	2	 

    	 

    

(c) Holder’s
Exercise Limitations.  The Company shall not effect any exercise of this Warrant, and a Holder shall not have the right to exercise
any portion of this Warrant, to the extent that after giving effect to issuance of Warrant Shares upon exercise as set forth on the applicable
Notice of Exercise, the Holder (together with the Holder’s Affiliates, and any other persons acting as a group together with the
Holder or any of the Holder’s Affiliates), would beneficially own in excess of the Beneficial Ownership Limitation, as defined below.
For purposes of the foregoing sentence, the number of shares of Common Stock beneficially owned by the Holder and its Affiliates shall
include the number of shares of Common Stock issuable upon exercise of this Warrant with respect to which such determination is being
made, but shall exclude the number of shares of Common Stock which would be issuable upon (i) exercise of the remaining, non-exercised
portion of this Warrant beneficially owned by the Holder or any of its Affiliates and (ii) exercise or conversion of the unexercised or
non-converted portion of any other securities of the Company (including without limitation any other Common Stock Equivalents) subject
to a limitation on conversion or exercise analogous to the limitation contained herein beneficially owned by the Holder or any of its
Affiliates. Except as set forth in the preceding sentence, for purposes of this paragraph (d), beneficial ownership shall be calculated
in accordance with Section 13(d) of the Exchange Act, it being acknowledged by the Holder that the Company is not representing to the
Holder that such calculation is in compliance with Section 13(d) of the Exchange Act and the Holder is solely responsible for any schedules
required to be filed in accordance therewith. To the extent that the limitation contained in this paragraph applies, the determination
of whether this Warrant is exercisable (in relation to other securities owned by the Holder together with any affiliates) and of which
portion of this Warrant is exercisable shall be in the sole discretion of the Holder, and the submission of a Notice of Exercise shall
be deemed to be the Holder’s determination of whether this Warrant is exercisable (in relation to other securities owned by the
Holder together with any Affiliates) and of which portion of this Warrant is exercisable, in each case subject to the Beneficial Ownership
Limitation, and the Company shall have no obligation to verify or confirm the accuracy of such determination.

 

For
purposes of this Section 1(c), in determining the number of outstanding shares of Common Stock, a Holder may rely on the number
of outstanding shares of Common Stock as reflected in (A) the Company’s most recent periodic or annual report filed with the Commission,
as the case may be, (B) a more recent public announcement by the Company or (C) a more recent written notice by the Company or its transfer
agent setting forth the number of shares of Common Stock outstanding. Upon the request of a Holder, the Company shall within two Trading
Days confirm to the Holder the number of shares of Common Stock then outstanding. In any case, the number of outstanding shares of Common
Stock shall be determined after giving effect to the conversion or exercise of securities of the Company, including this Warrant, by the
Holder or its affiliates since the date as of which such number of outstanding shares of Common Stock was reported. The “Beneficial
Ownership Limitation” shall be 4.99% of the number of shares of the Common Stock outstanding immediately after giving effect to
the issuance of shares of Common Stock issuable upon exercise of this Warrant. The limitations contained in this paragraph shall apply
to a successor Holder of this Warrant.

 

2. ADJUSTMENTS. 
The Exercise Price and the number of Warrant Shares shall be adjusted from time to time as follows:

 

(a) Distribution
of Assets.  If the Company shall declare or make any dividend or other distribution of its assets (or rights to acquire its assets)
to holders of shares of Common Stock, by way of return of capital or otherwise (including without limitation any distribution of cash,
stock or other securities, property or options by way of a dividend, spin off, reclassification, corporate rearrangement or other similar
transaction) (a “Distribution”), at any time after the issuance of this Warrant, then, in each such case:

 

    	 	3	 

    	 

    

(i) any
Exercise Price in effect immediately prior to the close of business on the record date fixed for the determination of holders of shares
of Common Stock entitled to receive the Distribution shall be adjusted, effective as of the close of business on such record date, to
a price determined by multiplying such Exercise Price by a fraction (i) the numerator of which shall be the Closing Sale Price of the
shares of Common Stock on the Trading Day immediately preceding such record date minus the value of the Distribution (as determined in
good faith by the Company’s Board of Directors) applicable to one share of Common Stock, and (ii) the denominator of which shall
be the Closing Sale Price of the shares of Common Stock on the Trading Day immediately preceding such record date; and

 

(ii) the
number of Warrant Shares shall be adjusted to a number of shares equal to the number of shares of Common Stock obtainable immediately
prior to the close of business on the record date fixed for the determination of holders of shares of Common Stock entitled to receive
the Distribution multiplied by the reciprocal of the fraction set forth in the immediately preceding clause (i); provided, however, that
in the event that the Distribution is of shares of common stock of a company (other than the Company) whose common stock is traded on
a national securities exchange or a national automated quotation system (“Other Shares of Common Stock”), then the Holder
may elect to receive a warrant to purchase Other Shares of Common Stock in lieu of an increase in the number of Warrant Shares, the terms
of which shall be identical to those of this Warrant, except that such warrant shall be exercisable into the number of shares of Other
Shares of Common Stock that would have been payable to the Holder pursuant to the Distribution had the Holder exercised this Warrant immediately
prior to such record date and with an aggregate exercise price equal to the product of the amount by which the exercise price of this
Warrant was decreased with respect to the Distribution pursuant to the terms of the immediately preceding clause (i) and the number of
Warrant Shares calculated in accordance with the first part of this clause (ii).  

 

3. FUNDAMENTAL
TRANSACTIONS.  If, at any time while this Warrant is outstanding, (i) the Company effects any merger of the Company with or into
another entity and the Company is not the surviving entity (such surviving entity, the “Successor Entity”), (ii) the Company
effects any sale of all or substantially all of its assets in one or a series of related transactions, (iii) any tender offer or exchange
offer (whether by the Company or by another individual or entity, and approved by the Company) is completed pursuant to which holders
of Common Stock are permitted to tender or exchange their shares of Common Stock for other securities, cash or property and the holders
of at least 50% of the Common Stock accept such offer, or (iv) the Company effects any reclassification of the Common Stock or any compulsory
share exchange pursuant to which the Common Stock is effectively converted into or exchanged for other securities, cash or property (other
than as a result of a subdivision or combination of shares of Common Stock) (in any such case, a “Fundamental Transaction”),
then, upon any subsequent exercise of this Warrant, the Holder shall have the right to receive the number of shares of Common Stock of
the Successor Entity or of the Company and any additional consideration (the “Alternate Consideration”) receivable upon or
as a result of such reorganization, reclassification, merger, consolidation or disposition of assets by a holder of the number of shares
of Common Stock for which this Warrant is exercisable immediately prior to such event (disregarding any limitation on exercise contained
herein solely for the purpose of such determination). For purposes of any such exercise, the determination of the Exercise Price shall
be appropriately adjusted to apply to such Alternate Consideration based on the amount of Alternate Consideration issuable in respect
of one share of Common Stock in such Fundamental Transaction, and the Company shall apportion the Exercise Price among the Alternate Consideration
in a reasonable manner reflecting the relative value of any different components of the Alternate Consideration. If holders of Common
Stock are given any choice as to the securities, cash or property to be received in a Fundamental Transaction, then the Holder shall be
given the same choice as to the Alternate Consideration it receives upon any exercise of this Warrant following such Fundamental Transaction.
To the extent necessary to effectuate the foregoing provisions, any Successor Entity in such Fundamental Transaction shall issue to the
Holder a new warrant consistent with the foregoing provisions and evidencing the Holder’s right to exercise such warrant into Alternate
Consideration.

    	 	4	 

    	 

    

4. NON-CIRCUMVENTION. 
The Company covenants and agrees that it will not, by amendment of its certificate of incorporation, bylaws or through any reorganization,
transfer of assets, consolidation, merger, scheme of arrangement, dissolution, issue or sale of securities, or any other voluntary action,
avoid or seek to avoid the observance or performance of any of the terms of this Warrant, and will at all times in good faith carry out
all the provisions of this Warrant and take all action as may be required to protect the rights of the Holder. Without limiting the generality
of the foregoing, the Company (i) shall not increase the par value of any shares of Common Stock receivable upon the exercise of this
Warrant above the Exercise Price then in effect, (ii) shall take all such actions as may be necessary or appropriate in order that the
Company may validly and legally issue fully paid and non-assessable shares of Common Stock upon the exercise of this Warrant, and (iii)
shall, for so long as this Warrant is outstanding, have authorized and reserved, free from preemptive rights, three times the number of
shares of Common Stock issuable under the Warrant, to provide for the exercise of the rights represented by this Warrant (without regard
to any limitations on exercise).

  

5. WARRANT
HOLDER NOT DEEMED A STOCKHOLDER.  Except as otherwise specifically provided herein, this Warrant, in and of itself, shall not entitle
the Holder to any voting rights or other rights as a stockholder of the Company. In addition, nothing contained in this Warrant shall
be construed as imposing any liabilities on the Holder to purchase any securities (upon exercise of this Warrant or otherwise) or as a
stockholder of the Company, whether such liabilities are asserted by the Company or by creditors of the Company.

 

6. REISSUANCE.

 (a) Lost,
Stolen or Mutilated Warrant.  If this Warrant is lost, stolen, mutilated or destroyed, the Company will, on such terms as to indemnity
or otherwise as it may reasonably impose (which shall, in the case of a mutilated Warrant, include the surrender thereof), issue a new
Warrant of like denomination and tenor as this Warrant so lost, stolen, mutilated or destroyed.

 

(b) Issuance
of New Warrants.  Whenever the Company is required to issue a new Warrant pursuant to the terms of this Warrant, such new Warrant
shall be of like tenor with this Warrant, and shall have an issuance date, as indicated on the face of such new Warrant which is the same
as the Issuance Date.

 

7. TRANSFER.

(a) Notice
of Transfer.  The Holder agrees to give written notice to the Company before transferring this Warrant or transferring any Warrant
Shares of such Holder’s intention to do so, describing briefly the manner of any proposed transfer. Promptly upon receiving such
written notice, the Company shall present copies thereof to the Company’s counsel. If the proposed transfer may be effected without
registration or qualification (under any federal or state securities laws), the Company, as promptly as practicable, shall notify the
Holder thereof, whereupon the Holder shall be entitled to transfer this Warrant or to dispose of Warrant Shares received upon the previous
exercise of this Warrant, all in accordance with the terms of the notice delivered by the Holder to the Company; provided, however, that
an appropriate legend may be endorsed on this Warrant or the certificates for such Warrant Shares respecting restrictions upon transfer
thereof necessary or advisable in the opinion of counsel and satisfactory to the Company to prevent further transfers which would be in
violation of Section 5 of the Securities Act and applicable state securities laws; and provided further that the prospective transferee
or purchaser shall execute the Assignment of Warrant attached hereto as Exhibit B and such other documents and make such representations,
warranties, and agreements as may be required solely to comply with the exemptions relied upon by the Company for the transfer or disposition
of the Warrant or Warrant Shares.

    	 	5	 

    	 

    

(b) If
the proposed transfer or disposition of this Warrant or such Warrant Shares described in the written notice given pursuant to this Section
7 may not be effected without registration or qualification of this Warrant or such Warrant Shares, the Holder will limit its activities
in respect to such transfer or disposition as are permitted by law.

 

(c) Any
transferee of all or a portion of this Warrant shall succeed to the rights and benefits of the initial Holder of this Warrant under the
Agreement (registration rights, expenses, and indemnity).

 

8. NOTICES. 
Whenever notice is required to be given under this Warrant, unless otherwise provided herein, such notice shall be given in accordance
with the notice provisions contained in the Agreement.  The Company shall provide the Holder with prompt written notice (i) immediately
upon any adjustment of the Exercise Price, setting forth in reasonable detail, the calculation of such adjustment and (ii) at least 20
days prior to the date on which the Company closes its books or takes a record (A) with respect to any dividend or distribution upon the
shares of Common Stock, (B) with respect to any grants, issuances or sales of any stock or other securities directly or indirectly convertible
into or exercisable or exchangeable for shares of Common Stock or other property, pro rata to the holders of shares of Common Stock or
(C) for determining rights to vote with respect to any Fundamental Transaction, dissolution or liquidation, provided in each case that
such information shall be made known to the public prior to or in conjunction with such notice being provided to the Holder.

 

9.   AMENDMENT
AND WAIVER.  The terms of this Warrant may be amended or waived (either generally or in a particular instance and either retroactively
or prospectively) only with the written consent of the Company and the Holder.

  

10. GOVERNING
LAW.  This Warrant shall be governed by and interpreted in accordance with the laws of the State of California without regard to
the principles of conflicts of law (whether of the State of California or any other jurisdiction).

 

11. ARBITRATION. 
Any disputes, claims, or controversies arising out of or relating to this Warrant, or the transactions, contemplated thereby, or the breach,
termination, enforcement, interpretation, or validity thereof, including the determination of the scope or applicability of this Warrant
to arbitrate, shall be referred to and resolved solely and exclusively by binding arbitration to be conducted before the Judicial Arbitration
and Mediation Service (“JAMS”), or its successor pursuant the expedited procedures set forth in the JAMS Comprehensive Arbitration
Rules and Procedures (the “Rules”), including Rules 16.1 and 16.2 of those Rules. The arbitration shall be held in Los Angeles,
California, before a tribunal consisting of three (3) arbitrators each of whom will be selected in accordance with the “strike and
rank” methodology set forth in Rule 15. Either party to this Warrant may, without waiving any remedy under this Warrant, seek from
any federal or state court sitting in the State of California any interim or provisional relief that is necessary to protect the rights
or property of that party, pending the establishment of the arbitral tribunal. The costs and expenses of such arbitration shall be paid
via equal split by the parties, with all such costs and expenses, including reasonable attorneys’ fees, to be awarded to the prevailing
party in such arbitration. The arbitrators’ decision must set forth a reasoned basis for any award of damages or finding of liability. 
The arbitrators’ decision and award will be made and delivered as soon as reasonably possible and in any case within sixty (60)
days’ following the conclusion of the arbitration hearing and shall be final and binding on the parties and may be entered by any
court having jurisdiction thereof.

    	 	6	 

    	 

    

12. JURY
TRIAL WAIVER.  THE COMPANY AND THE HOLDER HEREBY WAIVE A TRIAL BY JURY IN ANY ACTION, PROCEEDING OR COUNTERCLAIM BROUGHT BY EITHER
OF THE PARTIES HERETO AGAINST THE OTHER IN RESPECT OF ANY MATTER ARISING OUT OF OR IN CONNECTION WITH THIS WARRANT.

 

13. ACCEPTANCE. 
Receipt of this Warrant by the Holder shall constitute acceptance of and agreement to all of the terms and conditions contained herein.

 

14. CERTAIN
DEFINITIONS.  For purposes of this Warrant, the following terms shall have the following meanings:

 

(a) “Nasdaq”
means www.Nasdaq.com.

 

(b) “Closing
Sale Price” means, for any security as of any date, (i) the last closing trade price for such security on the Trading Market, or,
if the Trading Market begins to operate on an extended hours basis and does not designate the closing trade price, then the last trade
price of such security prior to 4:00 p.m., New York time, as reported by Nasdaq (or applicable Trading market), or (ii) if the foregoing
does not apply, the last trade price of such security in the over-the-counter market for such security as reported by Nasdaq (or applicable
Trading market), or (iii) if no last trade price is reported for such security by Nasdaq (or applicable Trading market), the average of
the bid and ask prices of any market makers for such security as reported by the OTC Markets. If the Closing Sale Price cannot be calculated
for a security on a particular date on any of the foregoing bases, the Closing Sale Price of such security on such date shall be the fair
market value as mutually determined by the Company and the Holder. All such determinations to be appropriately adjusted for any stock
dividend, stock split, stock combination or other similar transaction during the applicable calculation period.

 

(c) “Common
Stock” means the Company’s common stock and any other class of securities into which such securities may hereafter be reclassified
or changed.

 

(d) “Common
Stock Equivalents” means any securities of the Company that would entitle the holder thereof to acquire at any time Common Stock,
including without limitation any debt, preferred stock, rights, options, warrants or other instrument that is at any time convertible
into or exercisable or exchangeable for, or otherwise entitles the holder thereof to receive, Common Stock.

 

(e) “Trading
Market” means the NASDAQ Capital Market or any of the following markets or exchanges on which the Company’s Common Stock is
listed or quoted for trading on the applicable date: (i) the NASDAQ Global Market; (ii) the NASDAQ Select Market; (iii) the NYSE American;
and (iv) the New York Stock Exchange (or any successors to any of the foregoing) or (v) any tier of the OTC Markets.

 

(f)       “Market
Price” means the highest traded price of the Common Stock during the three hundred sixty-five (365) Trading Days prior to the date
of the respective Exercise Notice.

 

(g)      “Trading
Day” means (i) any day on which the Common Stock is listed or quoted and traded on its Trading Market, (ii) if the Common Stock
is not then listed or quoted and traded on any national securities exchange, then a day on which trading occurs on any over-the-counter
markets, or (iii) if trading does not occur on the over-the-counter markets, any Business Day.

 

(g)      “Valuation
Cap” means $190,000,000 divided by the outstanding share count, as reported by the transfer agent, of the Company the Business Day
prior to Exercise Notice.

    	 	7	 

    	 

    

IN WITNESS WHEREOF, the Company
has caused this Warrant to be duly executed as of the Issuance Date set forth above.

 

Company

By:__________

Name:__________

Title:__________

 

Agreed and Accepted:

Investor

By:__________

Name:__________

Title:__________

    	 	8	 

    	 

    

EXHIBIT A

 

EXERCISE NOTICE

 

(To be executed by the
registered holder to exercise this Common Stock Purchase Warrant)

 

The
Undersigned holder hereby exercises the right to purchase _________________ of the shares of Common Stock (“Warrant
Shares”) of Wikisoft Corp., a Nevada corporation (the “Company”), evidenced by the attached copy of the Common Stock
Purchase Warrant (the “Warrant”). Capitalized terms used herein and not otherwise defined shall have the respective meanings
set forth in the Warrant.

 

	 	1.	
    Form of Exercise
    Price.  The Holder intends that payment of the Exercise Price shall be made

    as (check one):

 

	 	☐	a cash exercise with respect to _________________ Warrant Shares; or
	 	☐	by cashless exercise pursuant to the Warrant.

 

	 	2.	
    Payment of Exercise
    Price.  If cash exercise is selected above, the holder shall pay the applicable

    Aggregate Exercise Price in the sum of $___________________
    to the Company in accordance with

    the terms of the Warrant.

 

	 	3.	
    Delivery of
    Warrant Shares.  The Company shall deliver to the holder __________________

    Warrant Shares in accordance with the terms of the
    Warrant.

 

 

Date:                                                 

 

 (Print Name of
Registered Holder)

 

 By: _________________________________________

 Name:_______________________________________

 Title:________________________________________

 

    	 	9	 

    	 

    

 

EXHIBIT B

 

ASSIGNMENT OF WARRANT

 

(To be signed only upon
authorized transfer of the Warrant)

 

For
Value Received, the undersigned hereby sells, assigns, and transfers unto ____________________ the right to purchase _______________
shares of Common Stock of __________ to which the within Common Stock Purchase Warrant relates and appoints ____________________, as attorney-in-fact,
to transfer said right on the books of __________ with full power of substitution and re-substitution in the premises.  By accepting
such transfer, the transferee has agreed to be bound in all respects by the terms and conditions of the within Warrant.

 

 

Date:                                                 

 

 ____________________________________

(Signature) *

 

 ____________________________________

(Name)

 

____________________________________

(Address)

 

 ____________________________________

(Social Security or Tax
Identification No.)

 

* The signature on this
Assignment of Warrant must correspond to the name as written upon the face of the Common Stock Purchase Warrant in every particular without
alteration or enlargement or any change whatsoever. When signing on behalf of a corporation, partnership, trust or other entity, please
indicate your position(s) and title(s) with such entity.

 

    	 	10COMMON STOCK PURCHASE AGREEMENT

 

This common stock purchase agreement
(the “Agreement”), dated as of June 8, 2021 (the “Execution Date”), is entered into between Wikisoft Corp., a
Nevada corporation (the “Company”), and TRITON FUNDS LP, a Delaware limited partnership (the “Investor”).

 

RECITALS:

 

WHEREAS, upon the terms and
subject to the conditions contained herein, the Investor shall purchase Seven Hundred Fifty Thousand Dollars ($750,000) of
Securities after a Registration Statement is declared effective by the Securities and Exchange Commission (the “SEC”) at
a fixed price of $1.50 per share; 

 

NOW THEREFORE, in consideration
of the foregoing recitals, which shall be considered an integral part of this Agreement, the covenants and agreements set forth hereafter,
and other good and valuable consideration, the receipt and sufficiency of which is hereby acknowledged, the Company and the Investor hereby
agree as follows:

 

SECTION I

DEFINITIONS

 

For all purposes of and under
this Agreement, the following terms shall have the respective meanings below, and such meanings shall be equally applicable to the singular
and plural forms of such defined terms.

  

“Administrative Fee” shall mean
25,000 Securities issued by the Company to the Investor upon execution of the Agreement and $10,000 deducted from the Investment Amount
at Closing.

 

“Business Day” shall mean any
day on which the Trading Market for the Common Stock is open for trading from the hours of 9:30 am until 4:00 pm eastern time.

 

“Closing” shall mean a
date that is no later than five (5) Business Days after the effectiveness of the Registration Statement and receipt of Effectiveness
Notice, notwithstanding anything to the contrary in this Agreement.

 

“Effectiveness Notice” shall
mean an irrevocable written notice from the Company to the Investor informing of effectiveness of the Registration Statement and directing
the Investor to purchase the Securities as referenced in Exhibit A of this Agreement.

 

“Common Stock” means the Company’s
common stock and any other class of securities into which such securities may hereafter be reclassified or changed.

 

“Investment Amount” shall mean
the Purchase Price multiplied by the number of Securities purchased at Closing.

 

“Purchase Price” shall mean
$1.50 per share.

 

“Registration Statement” means
the registration statement covering the Securities.

 

“Securities” shall
mean the Common Stock issued pursuant to the terms of this Agreement.

 

“Trading Market” shall mean
the New York Stock Exchange, the NYSE Amex, the Nasdaq Capital Market, the Nasdaq Global Market, the Nasdaq Global Select Market or any
tier of the OTC Markets, including OTC Pink, whichever is the market on which the Common Stock trades or is listed.

 

    	 		 

    	 

    

 

SECTION II

PURCHASE AND SALE OF SECURITIES

 

2.1 PURCHASE AND SALE
OF SECURITIES. Subject to the terms and conditions set forth herein, the Company shall sell to the Investor, and the Investor shall
purchase from the Company, at Closing a number of Securities equal to the Investment Amount.

 

2.2 CLOSING. Subject
to the terms and conditions herein, the Company will deliver the Effectiveness Notice upon the declaration of effectiveness of the Registration
Statement.

 

2.3 CONDITIONS TO INVESTOR’S
OBLIGATION TO PURCHASE SECURITIES. Notwithstanding anything to the contrary in this Agreement, the Investor may choose to reduce the
Investment Amount under this Agreement if at Closing (i) the Registration Statement is not effective, (ii) if the Common Stock has been
suspended from trading on the Trading Market, (iii) if there is an injunction issued and remaining in force or an action commenced by
a governmental authority prohibiting the purchase or the issuance of the Securities or (iv) if the Common Stock has traded below the Purchase
Price at the date of closing.

 

2.4 MECHANICS OF CLOSING.
The Closing shall occur no later than the 5 (five) Business Days following receipt of Securities by Investor’s custodian. At Closing,
the Investor shall deliver the Investment Amount by wire transfer of immediately available funds to an account designated by the Company.

 

2.5 LIMITATION ON AMOUNT
OF OWNERSHIP. Notwithstanding anything to the contrary in this Agreement, in no event shall the Investor be entitled to purchase that
number of Securities, which when added to the sum of the number of Common Stock beneficially owned (as such term is defined under Section
13(d) and Rule 13d-3 of the 1934 Act), by the Investor, would exceed 4.99% of the Common Stock outstanding at Closing, as determined in
accordance with Rule 13d-1(j) of the 1934 Act.

 

SECTION III

INVESTOR’S REPRESENTATIONS, WARRANTIES AND COVENANTS

   

3.1 NO SHORT SALES. No
short sales shall be permitted by the Investor or its affiliates.

 

3.2 INVESTMENT PURPOSE.
The Investor is entering into this Agreement and acquiring the Securities for investment purposes.

3.3 ACCREDITED INVESTOR
STATUS. The Investor is an “accredited investor” as that term is defined in Rule 501(a)(3) of Regulation D.

3.4 ACKNOWLEDGEMENT
OF TERMS. The Investor hereby represents and warrants to the Company that: (i) it is voluntarily entering into this Agreement of its
own freewill, (ii) it is not entering this Agreement under economic duress, (iii) the terms of this Agreement are reasonable and fair
to the Investor, and (iv) the Investor has had independent legal counsel of its own choosing review this Agreement, advise the Investor
with respect to this Agreement, and represent the Investor in connection with this Agreement.

3.5 DUE EXECUTION.
This Agreement, and any and all other documents required to be executed and delivered by the Investor pursuant to this Agreement, have
been duly executed and delivered by the Investor and constitute a valid, legal and binding obligation on the Investor that is enforceable
against the Investor in accordance with their terms.

3.6 NO CONFLICTS.
Neither the execution or delivery of this Agreement, nor any other documents required to be executed and delivered by the Investor hereunder,
nor the consummation of the transactions contemplated hereby conflicts with or constitutes any violation or breach, or gives any other
person any rights under any document or agreement that the Investor is a party to. Neither the Investor’s entry into this Agreement,
nor the Investor’s representations made in this Agreement, constitute a violation of any order or applicable law that the Investor
is subject to.

    	 	2	 

    	 

    

SECTION IV

REPRESENTATIONS AND WARRANTIES OF THE COMPANY

 

Except as disclosed on the Company’s
SEC Documents, the Company represents and warrants to the Investor that:

4.1 ORGANIZATION AND QUALIFICATION.
The Company is a corporation duly organized and validly existing in good standing under the laws of the State of Nevada, and has the requisite
corporate power and authorization to own its properties and to carry on its business as now being conducted. Both the Company and the
companies it owns or controls (“Subsidiaries”) are duly qualified to do business and are in good standing in every jurisdiction
in which its ownership of property or the nature of the business conducted by it makes such qualification necessary, except to the extent
that the failure to be so qualified or be in good standing would not have a Material Adverse Effect. As used in this Agreement, “Material
Adverse Effect” means a change, event, circumstance, effect or state of facts that has had or is reasonably likely to have, a material
adverse effect on the business, properties, assets, operations, results of operations, financial condition or prospects of the Company
and its Subsidiaries, if any, taken as a whole, or on the transactions contemplated hereby or by the agreements and instruments to be
entered into in connection herewith, or on the authority or ability of the Company to perform its obligations under the Agreement.

 

4.2 AUTHORIZATION; ENFORCEMENT;
COMPLIANCE WITH OTHER INSTRUMENTS.

 

	 	i.	
    The Company has the requisite corporate power and
    authority to enter into the Agreement

    and to issue the Securities in accordance with the
    terms hereof.

	 	 	 
	 	ii.	The execution and delivery of the Agreement by the Company and the consummation by it of the transactions contemplated hereby and thereby, including without limitation the issuance of the Securities pursuant to this Agreement, have been duly and validly authorized by the Company’s Board of Directors and no further consent or authorization is required by the Company, its Board of Directors, or its shareholders.

 

	 	iii.	 The Agreement has been duly and validly executed and delivered by the Company.
	 	 	 
	 	iv.	 This Agreement constitutes the valid and binding obligations of the Company enforceable against the Company in accordance with their terms, except as such enforceability may be limited by general principles of equity or applicable bankruptcy, insolvency, reorganization, moratorium, liquidation or similar laws relating to, or affecting generally, the enforcement of creditors’ rights and remedies.

 

4.3 ISSUANCE OF SECURITIES.
The Company will reserve the number of Securities included in the Company’s Registration Statement for issuance pursuant to the
Agreement, which have been duly authorized and reserved (subject to adjustment pursuant to the Company’s covenant set forth in Section
5.5 below) pursuant to this Agreement. Upon issuance in accordance with this Agreement, the Securities will be validly issued,
fully paid for and non-assessable and free from all taxes, liens and charges with respect to the issuance thereof. In the event the Company
cannot register a sufficient number of Securities for issuance pursuant to this Agreement, the Company will use its best efforts to authorize
and reserve for issuance the number of Securities required for the Company to perform its obligations hereunder as soon as reasonably
practicable.

 

4.4 DILUTIVE EFFECT.
The Company’s executive officers and directors have studied and fully understand the nature of the transactions contemplated by
this Agreement and recognize that they have a potential dilutive effect on the shareholders of the Company. The Board of Directors of
the Company has concluded, in its good faith business judgment, and with full understanding of the implications, that such issuance is
in the best interests of the Company. The Company specifically acknowledges that, subject to such limitations as are expressly set forth
in the Agreement, its obligation to issue Securities upon purchases pursuant to this Agreement is absolute and unconditional regardless
of the dilutive effect that such issuance may have on the ownership interests of other shareholders of the Company.

 

4.5 NO EXCLUSIVITY.
The Company may pursue a similar transaction with any other party during the time from the Execution Date to the Closing as well as prior
to then and thereafter.

 

    	 	3	 

    	 

    

 

SECTION V

COVENANTS OF THE COMPANY

 

5.1 BEST EFFORTS.
The Company shall use all commercially reasonable efforts to timely satisfy each of the conditions set forth in this Agreement.

 

5.2 REPORTING STATUS.
From the Execution Date and until Closing or until this Agreement terminates pursuant to Section 6, the Company shall file
all reports required to be filed with the SEC pursuant to the 1934 Act, and the Company shall not terminate its status, or take an action
or fail to take any action, which would terminate its status as a reporting company under the 1934 Act.

 

5.3 USE OF PROCEEDS.
The Company will use the proceeds from the sale of the Securities for general corporate and working capital purposes and acquisitions
or assets, businesses or operations or for other purposes that the Board of Directors, in good faith deem to be in the best interest of
the Company.

 

5.4 FINANCIAL INFORMATION.
During the time from the Execution Date and until Closing or until this Agreement terminates pursuant to Section 6, the Company
agrees to make available to the Investor via EDGAR or other electronic means the following documents and information on the forms set
forth: (i) within five (5) Business Days after the filing thereof with the SEC, a copy of its Annual Reports on Form 10-K, its Quarterly
Reports on Form 10-Q, any Current Reports on Form 8-K and any registration statements or amendments filed pursuant to the 1933 Act; (ii)
copies of any notices and other information made available or given to the shareholders of the Company generally, contemporaneously with
the making available or giving thereof to the shareholders; and (iii) within two (2) calendar days of filing or delivery thereof, copies
of all documents filed with, and all correspondence sent to, the Trading Market, any securities exchange or market, or the Financial Industry
Regulatory Association, unless such information is material nonpublic information.

 

5.5 RESERVATION OF SECURITIES.
The Company shall take all action necessary to at all times have authorized, and reserved the amount of Securities included in the Company’s
Registration Statement for issuance pursuant to the Agreement. In the event that the Company determines that it does not have a sufficient
number of Common Stock to reserve and keep available for issuance as described, the Company shall use all commercially reasonable efforts
to increase the number of Common Stock by seeking shareholder approval.

 

5.6 TRADING. The Company
shall maintain the trading of the Common Stock on the Trading Market or any other national securities exchange and automated quotation
system, if any, upon which Common Stock are then trading and shall maintain, such trading until earlier to occur, the Closing of this
Agreement terminated pursuant to Section 6. Neither the Company nor any of its Subsidiaries shall take any action which would be
reasonably expected to result in the delisting or suspension of the Common Stock on the Trading Market (excluding suspensions of not more
than one (1) Business Day resulting from business announcements by the Company). The Company shall promptly provide to the Investor copies
of any notices it receives from the Trading Market regarding the continued eligibility of the Common Stock for trading on such automated
quotation system or securities exchange. The Company shall pay all fees and expenses in connection with satisfying its obligations under
this Section 5.6.

 

5.7 CORPORATE EXISTENCE.
The Company shall use all commercially reasonable efforts to preserve and continue the corporate existence of the Company.

 

5.8 NOTICE OF CERTAIN
EVENTS AFFECTING REGISTRATION STATEMENT. The Company shall promptly notify the Investor upon the occurrence of any of the following
events in respect of the Registration Statement: (i) receipt of any request for additional information by the SEC or any other federal
or state governmental authority during the period of effectiveness of the Registration Statement for amendments or supplements to the
Registration Statement; (ii) the issuance by the SEC or any other federal or state governmental authority of any stop order suspending
the effectiveness of any Registration Statement or the initiation of any proceedings for that purpose; (iii) receipt of any notification
with respect to the suspension of the qualification or exemption from qualification of any of the Securities for sale in any jurisdiction
or the initiation or notice of any proceeding for such purpose; (iv) the happening of any event that makes any statement made in such
Registration Statement or related prospectus or any document incorporated or deemed to be incorporated therein by reference untrue in
any material respect or that requires the making of any changes in the Registration Statement related prospectus or documents so that,
in the case of an Registration Statement, it will not contain any untrue statement of a material fact or omit to state any material fact
required to be stated therein or necessary to make the statements therein not misleading, and that in the case of the related prospectus,
it will not contain any untrue statement of a material fact or omit to state any material fact required to be stated therein or necessary
to make the statements therein, in the light of the circumstances under which they were made, not misleading; and (v) the Company’s
reasonable determination that a post-effective amendment or supplement to the Registration Statement would be appropriate, and the Company
shall promptly make available to Investor any such supplement or amendment to the related prospectus.

 

    	 	4	 

    	 

    

 

5.9 TRANSFER AGENT.
The Company shall deliver instructions to its transfer agent to issue Securities to the Investor that are issued to the Investor pursuant
to this Agreement.

 

5.10 ACKNOWLEDGEMENT OF TERMS.
The Company hereby represents and warrants to the Investor that: (i) it is voluntarily entering into this Agreement of its own freewill,
(ii) it is not entering this Agreement under economic duress, (iii) the terms of this Agreement are reasonable and fair to the Company,
and (iv) the Company has had independent legal counsel of its own choosing review this Agreement, advise the Company with respect to this
Agreement, and represent the Company in connection with this Agreement.

  

SECTION VI

EXPIRATION

 

6.1 TERMINATION. This Agreement
shall expire on the earlier of to occur (i) the Closing or (ii) December 31, 2021.

   

SECTION VII

INTENTIONALLY LEFT BLANK

  

SECTION VIII

GOVERNING LAW, LEGAL FEES, SURVIVAL

 

8.1 LAW GOVERNING THIS
AGREEMENT. This Agreement shall be governed by and construed in accordance with the laws of the State of California without regard
to principles of conflicts of laws. Any action brought by either party against the other concerning the transactions contemplated by this
Agreement shall be brought only in the state or federal courts located in Los Angeles, California. The parties to this Agreement hereby
irrevocably waive any objection to jurisdiction and venue of any action instituted hereunder and shall not assert any defense based on
lack of jurisdiction or venue or based upon forum non conveniens. The parties executing this Agreement and other agreements
referred to herein or delivered in connection herewith on behalf of the Company agree to submit to the in personam jurisdiction of such
courts and hereby irrevocably waive trial by jury. The prevailing party shall be entitled to recover from the other party its reasonable
attorney’s fees and costs. In the event that any provision of this Agreement or any other agreement delivered in connection herewith
is invalid or unenforceable under any applicable statute or rule of law, then such provision shall be deemed inoperative to the extent
that it may conflict therewith and shall be deemed modified to conform with such statute or rule of law. Any such provision which may
prove invalid or unenforceable under any law shall not affect the validity or enforceability of any other provision of any agreement.
Each party hereby irrevocably waives personal service of process and consents to process being served in any suit, action or proceeding
in connection with this Agreement by mailing a copy thereof via registered or certified mail or overnight delivery (with evidence of delivery)
to such party at the address in effect for notices to it under this Agreement and agrees that such service shall constitute good and sufficient
service of process and notice thereof. Nothing contained herein shall be deemed to limit in any way any right to serve process in any
other manner permitted by law.

 

8.2 LEGAL FEES; AND MISCELLANEOUS
FEES. Except as otherwise set forth in the Agreement, including but not limited to the Administrative Fee, each party shall pay the
fees and expenses of its advisers, counsel, the accountants and other experts, if any, and all other expenses incurred by such party incident
to the negotiation, preparation, execution, delivery and performance of this Agreement. Any attorneys’ fees and expenses incurred
by either the Company or the Investor in connection with the preparation, negotiation, execution and delivery of any amendments to this
Agreement or relating to the enforcement of the rights of any party, after the occurrence of any breach of the terms of this Agreement
by another party or any default by another party in respect of the transactions contemplated hereunder, shall be paid on demand by the
party which breached this Agreement and/or defaulted, as the case may be.

 

8.3 SURVIVAL. The
representations and warranties of the Company and the Investor contained in this Agreement shall survive the Closing and the expiration
of this Agreement.

 

    	 	5	 

    	 

    

 

SECTION IX

NON-DISCLOSURE OF NON-PUBLIC INFORMATION

 

The Company shall not disclose
non-public information to the Investor.

 

Your signature on this Signature
Page evidences your agreement to be bound by the terms and conditions of this Agreement as of the date first written above. The undersigned
signatory hereby certifies that he has read and understands this Agreement, and the representations made by the undersigned in this Agreement
are true and accurate, and agrees to be bound by its terms.

 

	 	
    Company

     

    By: /s/ Carsten Falk

    Name: Carsten Falk

    Title: Chief Executive Officer

     

     

	
     

     
	
    Investor

     

    By: /s/ Jared Alexandria

	 	
    Name: Jared Alexandria

    Title: Principal

 

 

EFFECTIVENESS NOTICE

 

Date __________

 

 

	Investor,	

 

This is to inform you that as
of today the Company’s Registration Statement has been declared effective by the Securities and Exchange Commission and the Company
directs the Investor to purchase under this Agreement, $750,000 of Securities, which consist of 500,000 of the Company’s common
stock shares.

  

Regards,

 

Company

 

By: _________

Name: Carsten Falk

Title: Chief Executive Officer

 

    	 	6

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00329-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00329-of-00352.parquet"}]]